Soo, Ross A

Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study

Solomon, B. J., Besse, B., Bauer, T. M., Felip, E., Soo, R. A., Camidge, D. R., Chiari, R., Bearz, A., Lin, C.-C., Gadgeel, S. M., et al. (2018) · The Lancet Oncology

Lung Cancer Treatments and MutationsLung Cancer Research Studies

Cited by 791

Glycine decarboxylase activity drives non-small cell lung cancer tumor-initiating cells and tumorigenesis

Zhang, W. C., Shyh-Chang, N., Yang, H., Rai, A., Umashankar, S., Ma, S., Soh, B. S., Sun, L. L., Tai, B. C., Nga, M. E., et al. (2012) · Cell

Cancer, Hypoxia, and MetabolismCancer Cells and Metastasis

Cited by 660

Structural, Biochemical, and Clinical Characterization of Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations in Lung Cancer

Yasuda, H., Park, E., Yun, C.-H., Sng, N. J., Lucena-Araujo, A. R., Yeo, W.-L., Huberman, M. S., Cohen, D. W., Nakayama, S., Ishioka, K., et al. (2013) · Science Translational Medicine

Lung Cancer Treatments and MutationsHER2/EGFR in Cancer Research

Cited by 571

Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study

Garassino, M. C., Cho, B.-C., Kim, J.-H., Mazières, J., Vansteenkiste, J., Lena, H., Corral Jaime, J., Gray, J. E., Powderly, J., Chouaid, C., et al. (2018) · The Lancet Oncology

Cancer Immunotherapy and BiomarkersLung Cancer Treatments and Mutations

Cited by 568

A common BIM deletion polymorphism mediates intrinsic resistance and inferior responses to tyrosine kinase inhibitors in cancer

Ng, K. P., Hillmer, A. M., Chuah, C. T. H., Juan, W. C., Ko, T. K., Teo, A. S. M., Ariyaratne, P. N., Takahashi, N., Sawada, K., Fei, Y., et al. (2012) · Nature Medicine

Cell death mechanisms and regulationLung Cancer Treatments and Mutations

Cited by 557

Prognostic significance of thymidylate synthase, dihydropyrimidine dehydrogenase and thymidine phosphorylase protein expression in colorectal cancer patients treated with or without 5-fluorouracil-based chemotherapy.

Soong, R., Shah, N., Salto-Tellez, M., Tai, B. C., Soo, R. A., Han, H. C., Ng, S. S., Tan, W. L., Zeps, N., Joseph, D., et al. (2008) · Annals of Oncology

Colorectal Cancer Treatments and StudiesGenetic factors in colorectal cancer

Cited by 136

Next-generation epidermal growth factor receptor tyrosine kinase inhibitors in epidermal growth factor receptor -mutant non-small cell lung cancer

Tan, C.-S., Cho, B.-C., & Soo, R. A. (2016) · Lung Cancer

Lung Cancer Treatments and MutationsHER2/EGFR in Cancer Research

Cited by 105

Sequential Afatinib and Osimertinib in Patients with EGFR Mutation-Positive Non-Small-Cell Lung Cancer: Updated Analysis of the Observational Giotag Study

Hochmair, M. J., Morabito, A., Hao, D., Yang, C.-T., Soo, R. A., Yang, J. C.-H., Gucalp, R., Halmos, B., Wang, L., Märten, A., et al. (2019) · Future Oncology

Lung Cancer Treatments and MutationsLung Cancer Diagnosis and Treatment

Cited by 85

Impact of afatinib dose modification on safety and effectiveness in patients with EGFR mutation-positive advanced NSCLC: Results from a global real-world study (RealGiDo)

Halmos, B., Tan, E.-H., Soo, R. A., Cadranel, J., Lee, M. K., Foucher, P., Hsia, T.-C., Hochmair, M., Griesinger, F., Hida, T., et al. (2019) · Lung Cancer

Lung Cancer Treatments and MutationsLung Cancer Diagnosis and Treatment

Cited by 74

Microfluidic platform for negative enrichment of circulating tumor cells

Sajay, B. N. G., Chang, C.-P., Ahmad, H., Khuntontong, P., Wong, C. C., Wang, Z., Puiu, P. D., Soo, R., & Rahman, A. R. A. (2014) · Biomedical Microdevices

Microfluidic and Bio-sensing TechnologiesMicrofluidic and Capillary Electrophoresis Applications

Cited by 56

The positive impact of cytological specimens for EGFR mutation testing in non-small cell lung cancer: a single South East Asian laboratory's analysis of 670 cases

Pang, B., Matthias, D., Ong, C. W., Dhewar, A. N., Gupta, S., Lim, G. L., Nga, M. E., Seet, J. E., Qasim, A., Chin, T. M., et al. (2012) · Cytopathology

Lung Cancer Treatments and MutationsLung Cancer Diagnosis and Treatment

Cited by 47

Targeting SALL4 by entinostat in lung cancer

Yong, K. J., Li, A., Ou, W.-B., Hong, C. K. Y., Zhao, W., Wang, F., Tatetsu, H., Yan, B., Qi, L., Fletcher, J. A., et al. (2016) · Oncotarget

Histone Deacetylase Inhibitors ResearchLung Cancer Research Studies

Cited by 41

Dacomitinib in lung cancer: a “lost generation” EGFR tyrosine-kinase inhibitor from a bygone era?

Ou, S.-H., & Soo, R. (2015) · Drug Design, Development and Therapy

Lung Cancer Treatments and MutationsHER2/EGFR in Cancer Research

Cited by 28